A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation Article

Full Text via DOI: 10.1182/blood-2023-181151 Web of Science: 001159900803239

Cited authors

  • Goldberg AD, Samaniego F, Ohanian M, Koller PB, Chandhok NS, Sadiq AA, Mahadevan D, Cherry MA, Altman JK, Burke JM, Koontz MZ, Villasboas JCC, Tomlinson B, Finn LE, Reid EG, Melear J, Priego V, Cobb P, Heritage E, Conkling P, Cosgrove D, Roeker LE, Tam E, Haney DN, Hu J, Sinha R, Khan N, Rice WG, Bejar R

Authors

Publication date

  • 2023

Published in

International Standard Serial Number (ISSN)

  • 0006-4971

Number of pages

  • 6

Volume

  • 142